Company Overview
Immuneering Corporation functions as a late-stage oncology company dedicated to developing medicines intended for broad populations of cancer patients within the United States. The primary focus of its development pipeline includes IMM-1-104, known as atebimetinib, which is being utilized as a dual-MEK inhibitor currently undergoing a Phase 3 clinical trial to treat patients with various forms of cancer, including pancreatic cancer. This entity operates within the healthcare sector and specifically inside the biotechnology industry, a classification that defines its reliance on research, development, and clinical testing rather than mature manufacturing or retail operations. The company currently maintains a market capitalization of $343.95M and employs 53 individuals to support its scientific and operational objectives.
Financial Health
The financial statements for Immuneering Corporation reflect a net income of $-56,024,896 and an EBITDA of $-59,022,184 for the trailing twelve months, while revenue and sales data are not available for reporting. The substantial negative gap between the reported net income and EBITDA, alongside the absence of positive revenue figures, indicates that the company is in a stage where operational expenses and research costs are significantly exceeding any income generated from product sales or licensing. Free cash flow stands at $-28,047,836, which signifies that the company is consuming cash reserves to fund its clinical trials and development activities rather than generating surplus liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that characterizes a pre-revenue biotechnology firm where no profitable sales have yet been realized to offset overheads. The balance sheet holds $172.83M in cash against $3.82M in debt, resulting in a debt-to-equity ratio of 1.75, which suggests a capital structure that relies heavily on equity financing but maintains a manageable level of absolute debt. Despite the high debt-to-equity ratio, the current ratio is an exceptionally high 17.50, indicating that the company possesses a massive buffer of liquid assets relative to its short-term obligations. Return on Equity is -43.1% and Return on Assets is -26.1%, metrics that reveal that management effectiveness is currently measured by the preservation of capital rather than the generation of returns, as the company has not yet achieved commercial success.
Valuation Assessment
Valuation metrics for Immuneering Corporation present a challenging picture due to the lack of earnings, with a trailing P/E ratio listed as N/A and a forward P/E of -3.93. The negative forward P/E implies that analysts or the market is pricing the stock based on expectations of future profitability that have not yet materialized in current earnings data. The price-to-book ratio is 1.57, indicating that the market values the company at 57% above its book value, a premium often seen in biotech firms where intangible assets like intellectual property drive value despite low tangible net worth. Alternative valuation metrics such as the price-to-sales ratio are N/A and the EV/EBITDA is -2.96, suggesting that traditional multiple-based comparisons with profitable peers are not applicable and that the valuation relies heavily on asset backing and pipeline potential. The stock has traded between a 52-week high of $10.08 and a 52-week low of $1.10, providing a wide range of historical volatility for investors to analyze. The beta value is 0.45, which indicates that the stock price has historically exhibited significantly lower volatility relative to the broader market, moving with less intensity than the overall index.
Growth & Income
Growth metrics for Immuneering Corporation show that revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, reflecting the company's status as a pre-commercial entity where historical growth rates are not yet applicable. The absence of positive earnings growth means the company is not yet in a phase of scaling profits, but rather in a phase of scaling investment in clinical development. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash flow is retained to fund operations and research. Consequently, the overall growth and income profile is defined entirely by the progression of its clinical pipeline and the potential for future revenue generation rather than current cash distributions or historical growth rates.